Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows

Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows …C0NTINUE READING HERE >>>

Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free for over three years of using the drug, according to new data from the drugmaker Eli Lilly.

The findings come from the Surmount-1 trial, the company’s longest study of tirzepatide to date. Tirzepatide is sold as Zepbound for treating obesity and Mounjaro for treating diabetes.

The trial primarily measured how well weekly tirzepatide injections protected…

>